Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 11

Therapeutics Development 12

Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Overview 12

Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis 13

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Development by Companies 14

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Investigation by Universities/Institutes 19

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Development by Companies 23

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Investigation by Universities/Institutes 28

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Companies Involved in Therapeutics Development 29

AB Science 29

AbbVie Inc. 30

Adamis Pharmaceuticals Corporation 31

Advaxis, Inc. 32

Ambrx, Inc. 33

Amgen Inc. 34

Arrowhead Research Corporation 35

AstraZeneca Plc 36

ATLAB Pharma SAS 37

Bavarian Nordic A/S 38

Bellicum Pharmaceuticals, Inc. 39

BIND Therapeutics, Inc. 40

Boehringer Ingelheim GmbH 41

Bristol-Myers Squibb Company 42

Celgene Corporation 43

CellCentric Ltd 44

DexTech Medical AB 45

Eli Lilly and Company 46

Emergent BioSolutions Inc. 47

F. Hoffmann-La Roche Ltd. 48

Genentech, Inc. 49

GenSpera, Inc. 50

GlaxoSmithKline Plc 51

GTx, Inc. 52

Johnson & Johnson 53

Karyopharm Therapeutics, Inc. 54

Medivation, Inc. 55

Millennium Pharmaceuticals, Inc. 56

NewLink Genetics Corporation 57

Novartis AG 58

Oncogenex Pharmaceuticals, Inc. 59

Oncolytics Biotech Inc. 60

Onyx Pharmaceuticals, Inc. 61

Orion Oyj 62

Pfizer Inc. 63

Progenics Pharmaceuticals, Inc. 64

Sanofi 65

Sotio a.s. 66

Sun Pharma Advanced Research Company Ltd. 67

Supratek Pharma Inc. 68

Synta Pharmaceuticals Corp. 69

Takeda Pharmaceutical Company Limited 70

Tokai Pharmaceuticals, Inc. 71

TRACON Pharmaceuticals, Inc. 72

Viralytics Ltd. 73

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics Assessment 74

Assessment by Monotherapy Products 74

Assessment by Target 75

Assessment by Mechanism of Action 79

Assessment by Route of Administration 82

Assessment by Molecule Type 84

Drug Profiles 86

abiraterone acetate-Drug Profile 86

ABS-001-Drug Profile 89

Adipotide-Drug Profile 90

ADXS-PSA-Drug Profile 91

afuresertib hydrochloride-Drug Profile 93

apatorsen-Drug Profile 95

APC-200-Drug Profile 97

APC-300-Drug Profile 98

ASN-001-Drug Profile 99

ATL-101-Drug Profile 100

AZD-5312-Drug Profile 102

AZD-5363-Drug Profile 103

BI-836845-Drug Profile 105

BMTP-11-Drug Profile 107

BPX-201-Drug Profile 108

cabazitaxel-Drug Profile 109

cabazitaxel-Drug Profile 111

carfilzomib-Drug Profile 112

CC-115-Drug Profile 116

Cell Therapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 117

CFG-920-Drug Profile 118

crizotinib-Drug Profile 119

custirsen sodium-Drug Profile 123

CVA-21-Drug Profile 127

Dendritic Cell Therapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 131

docetaxel-Drug Profile 132

docetaxel-Drug Profile 134

DPV-001-Drug Profile 135

emibetuzumab-Drug Profile 137

enzalutamide-Drug Profile 138

erismodegib-Drug Profile 141

ES-414-Drug Profile 144

everolimus-Drug Profile 145

galeterone-Drug Profile 151

ganetespib-Drug Profile 153

GSK-2636771-Drug Profile 157

GTx-758-Drug Profile 158

idasanutlin-Drug Profile 160

indoximod-Drug Profile 162

ipilimumab-Drug Profile 164

JNJ-56021927-Drug Profile 168

LY-3022855-Drug Profile 170

LY-3023414-Drug Profile 171

masitinib-Drug Profile 173

mipsagargin-Drug Profile 176

Monoclonal Antibody Drug Conjugate to Inhibit PSMA for GBM and CRPC-Drug Profile 178

MVI-816-Drug Profile 179

navitoclax dihydrochloride-Drug Profile 181

ODM-201-Drug Profile 183

ODM-204-Drug Profile 185

olaparib-Drug Profile 186

olaratumab-Drug Profile 190

ONC-113B-Drug Profile 192

Osteodex-Drug Profile 193

pelareorep-Drug Profile 194

Protein for Prostate Cancer-Drug Profile 199

PSMA ADC-Drug Profile 200

RG-7450-Drug Profile 202

rilimogene galvacirepvec-Drug Profile 203

rilotumumab-Drug Profile 206

sapanisertib-Drug Profile 208

selinexor-Drug Profile 210

Small Molecule to Antagonize Androgen Receptor for Prostate Cancer-Drug Profile 215

Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer-Drug Profile 216

Small Molecules to Inhibit Bromodomain for Prostate Cancer-Drug Profile 217

Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer-Drug Profile 218

stapuldencel-t-Drug Profile 219

TL-118-Drug Profile 221

TRC-105-Drug Profile 223

Vaccine for Prostate Cancer-Drug Profile 226

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 229

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Recent Pipeline Updates 231

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects 356

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products 360

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Product Development Milestones 362

Featured News & Press Releases 362

Appendix 372

Methodology 372

Coverage 372

Secondary Research 372

Primary Research 372

Expert Panel Validation 372

Contact Us 372

Disclaimer 373

List of Tables

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Development by Companies, H1 2015 (Contd..4) 32

Products under Investigation by Universities/Institutes, H1 2015 33

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AB Science, H1 2015 34

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AbbVie Inc., H1 2015 35

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 36

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Advaxis, Inc., H1 2015 37

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Ambrx, Inc., H1 2015 38

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Amgen Inc., H1 2015 39

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Arrowhead Research Corporation, H1 2015 40

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AstraZeneca Plc, H1 2015 41

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by ATLAB Pharma SAS, H1 2015 42

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 43

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 44

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by BIND Therapeutics, Inc., H1 2015 45

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 46

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 47

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Celgene Corporation, H1 2015 48

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by CellCentric Ltd, H1 2015 49

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by DexTech Medical AB, H1 2015 50

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Eli Lilly and Company, H1 2015 51

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Emergent BioSolutions Inc., H1 2015 52

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Genentech, Inc., H1 2015 54

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GenSpera, Inc., H1 2015 55

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 56

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GTx, Inc., H1 2015 57

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Johnson & Johnson, H1 2015 58

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 59

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Medivation, Inc., H1 2015 60

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 61

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 62

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Novartis AG, H1 2015 63

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 64

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 65

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 66

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Orion Oyj, H1 2015 67

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Pfizer Inc., H1 2015 68

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 69

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sanofi, H1 2015 70

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sotio a.s., H1 2015 71

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 72

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Supratek Pharma Inc., H1 2015 73

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 74

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Tokai Pharmaceuticals, Inc., H1 2015 76

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 77

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Viralytics Ltd., H1 2015 78

Assessment by Monotherapy Products, H1 2015 79

Number of Products by Stage and Target, H1 2015 81

Number of Products by Stage and Mechanism of Action, H1 2015 85

Number of Products by Stage and Route of Administration, H1 2015 88

Number of Products by Stage and Molecule Type, H1 2015 90

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics-Recent Pipeline Updates, H1 2015 236

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects, H1 2015 361

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..1), H1 2015 362

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..2), H1 2015 363

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..3), H1 2015 364

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products, H1 2015 365

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products (Contd..1), H1 2015 366

List of Figures

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Products, H1 2015 27

Assessment by Monotherapy Products, H1 2015 79

Number of Products by Top 10 Targets, H1 2015 80

Number of Products by Stage and Top 10 Targets, H1 2015 80

Number of Products by Top 10 Mechanism of Actions, H1 2015 84

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 84

Number of Products by Top 10 Routes of Administration, H1 2015 87

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87

Number of Products by Top 10 Molecule Types, H1 2015 89

Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

Adamis Pharmaceuticals Corporation

Advaxis, Inc.

Ambrx, Inc.

Amgen Inc.

Arrowhead Research Corporation

AstraZeneca Plc

ATLAB Pharma SAS

Bavarian Nordic A/S

Bellicum Pharmaceuticals, Inc.

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

CellCentric Ltd

DexTech Medical AB

Eli Lilly and Company

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

GenSpera, Inc.

GlaxoSmithKline Plc

GTx, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Medivation, Inc.

Millennium Pharmaceuticals, Inc.

NewLink Genetics Corporation

Novartis AG

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Onyx Pharmaceuticals, Inc.

Orion Oyj

Pfizer Inc.

Progenics Pharmaceuticals, Inc.

Sanofi

Sotio a.s.

Sun Pharma Advanced Research Company Ltd.

Supratek Pharma Inc.

Synta Pharmaceuticals Corp.

Takeda Pharmaceutical Company Limited

Tokai Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

Viralytics Ltd.

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Products under Development, Key Players in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Overview, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com